High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma

Wei,Can; Wu,Song; Li,Xianxin; Wang,Yadong; Ren,Rui; Lai,Yongqing; Ye,Jiongxian

doi:10.3892/ol.2012.1032

High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma

Authors:
- Can Wei
- Song Wu
- Xianxin Li
- Yadong Wang
- Rui Ren
- Yongqing Lai
- Jiongxian Ye
View Affiliations

Affiliations: Medical Department, The University of Hong Kong-Shenzhen Hospital, Shenzhen, P.R. China, Department of Urology, Peking University Shenzhen Hospital, Shenzhen, P.R. China, Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen P.R. China, Medical Department, The First Clinical College, Anhui Medical University, Hefei, P.R. China
Published online on: November 16, 2012 https://doi.org/10.3892/ol.2012.1032
Pages: 473-478

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

FER tyrosine kinase (FER) has been demonstrated to play a critical role in tumorigenesis and metastasis; however, its potential value as a novel prognostic marker for clear cell renal cell carcinoma (ccRCC) remains unclear. In 48 paired samples of ccRCCs and normal adjacent tissues (ADTs), real‑time PCR was used to evaluate the expression of FER mRNA. The expression of FER protein was assessed in 87 ADTs and 206 samples of ccRCC using immunohistochemical methods. Statistical analysis was used to examine the correlations between the expression levels of FER and the clinical characteristics of ccRCC patients. A significant difference was identified between ccRCC tissues and ADTs in the mRNA levels of FER. Immunohistochemistry analyses revealed higher expression of FER protein in 87 ccRCC samples compared to the paired ADTs. In addition, FER protein expression in 206 ccRCC samples was significantly correlated with tumor size, T stage, N classification, metastasis, recurrence and Fuhrman grade, while associations with age and gender were not identifed. The Kaplan-Meier survival analysis showed that patients with high FER levels had a poorer survival outcome compared with those with lower levels. The log-rank test demonstrated that the cumulative survival rates were significantly different between the two groups. The Cox regression analysis indicated that FER expression, N stage and distant metastasis were independent prognostic factors for overall survival of ccRCC patients. Our results indicate that overexpression of FER in tumor tissues predicts a poor prognosis of patients with ccRCC, and FER may serve as a novel prognostic marker for ccRCC.

View Figures

View References

1.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Zbar B, Klausner R and Linehan WM: Studying cancer families to identify kidney cancer genes. Annu Rev Med. 54:217–233. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Wei X, Zhou L, Hu L and Huang Y: Tanshinone IIA arrests cell cycle and induces apoptosis in 786-O human renal cell carcinoma cells. Oncol Lett. 3:1144–1148. 2012.PubMed/NCBI
4.	Chong PK, Lee H, Kong JW, Loh MC, Wong CH and Lim YP: Phosphoproteomics, oncogenic signaling and cancer research. Proteomics. 8:4370–4382. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Greer P: Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol. 3:278–289. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Tsujita K, Suetsugu S, Sasaki N, Furutani M, Oikawa T and Takenawa T: Coordination between the actin cytoskeleton and membrane deformation by a novel membrane tubulation domain of PCH proteins is involved in endocytosis. J Cell Biol. 172:269–279. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Pasder P, Salem Y, Yaffe E, Shpungin S and Nir U: FER as a novel target for cancer therapy. Drugs Fut. 32:61–70. 2007. View Article : Google Scholar
8.	Li H, Ren Z, Kang X, Zhang L, Li X, Wang Y, Xue T, Shen Y and Liu Y: Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer. 9:3662009. View Article : Google Scholar
9.	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
10.	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta] CT method. Methods. 25:402–408. 2001.
11.	Schrader A, Sevinc S, Olbert P, Hegele A, Varga Z and Hofmann R: Gender-specific characteristics and survival of renal cell carcinoma. Urologe A. 47:1184–1186. 2008.PubMed/NCBI
12.	Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, Weight CJ and Campbell SC: A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urology. 178:429–434. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R and Zhou M: Differential expression of caveolin-1 in renal neoplasms. Cancer. 110:776–782. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Paulson R, Jackson J, Immergluck K and Bishop JM: The DFer gene of Drosophila melanogaster encodes two membrane-associated proteins that can both transform vertebrate cells. Oncogene. 14:641–652. 1997.PubMed/NCBI
15.	Letwin K, Yee SP and Pawson T: Novel protein-tyrosine kinase cDNAs related to fps/fes and eph cloned using anti-phosphotyrosine antibody. Oncogene. 3:621–627. 1988.PubMed/NCBI
16.	Piedra J, Miravet S, Castaño J, Pálmer HG, Heisterkamp N, García de Herreros A and Duñach M: p120 Catenin-associated Fer and Fyn tyrosine kinases regulate β-catenin Tyr-142 phosphorylation and β-catenin-α-catenin Interaction. Mol Cell Biol. 23:2287–2297. 2003.PubMed/NCBI
17.	Xu G, Craig AWB, Greer P, Miller M, Anastasiadis PZ, Lilien J and Balsamo J: Continuous association of cadherin with β-catenin requires the non-receptor tyrosine-kinase Fer. J Cell Sci. 117:3207–3219. 2004.
18.	Daly RJ: Cortactin signalling and dynamic actin networks. Biochem J. 382:13–25. 2004. View Article : Google Scholar : PubMed/NCBI
19.	El Sayegh TY, Arora PD, Laschinger CA, Lee W, Morrison C, Overall CM, Kapus A and McCulloch CA: Cortactin associates with N-cadherin adhesions and mediates intercellular adhesion strengthening in fibroblasts. J Cell Sci. 117:5117–5131. 2004.PubMed/NCBI
20.	Lu HY, Mao WM, Cheng QY, Chen B, Cai JF, Wang XJ, Wang Z and Xie FJ: Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett. 3:1288–1292. 2012.PubMed/NCBI
21.	Ben-Dor I, Bern O, Tennenbaum T and Nir U: Cell cycle-dependent nuclear accumulation of the p94fer tyrosine kinase is regulated by its NH2 terminus and is affected by kinase domain integrity and ATP binding. Cell Growth Differ. 10:113–129. 1999.PubMed/NCBI
22.	Pasder O, Shpungin S, Salem Y, Makovsky A, Vilchick S, Michaeli S, Malovani H and Nir U: Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells. Oncogene. 25:4194–4206. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P and La Vecchia C: The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 101:949–958. 2008. View Article : Google Scholar : PubMed/NCBI